ResearcherDalian Medical UniversityActive in the last 2 years

Ke Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6153-6912; OpenAlex author ID A5100365729. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2023: 1 paper · 2024: none · 2025: 1 paper

Papers 2

Targeting protein modification: a new direction for immunotherapy of pancreatic cancer. First author DOI 10.7150/ijbs.101861 ↗
Advancement of single-cell sequencing for clinical diagnosis and treatment of pancreatic cancer. Co-author DOI 10.3389/fmed.2023.1213136 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Xinyu Ge · 2 shared papers, 2023–2025 · strength 0.47
- Paper Targeting protein modification: a new direction for immunotherapy of pancreatic cancer. DOI 10.7150/ijbs.101861 ↗
- Paper Advancement of single-cell sequencing for clinical diagnosis and treatment of pancreatic cancer. DOI 10.3389/fmed.2023.1213136 ↗
Jie Zhu · 2 shared papers, 2023–2025 · strength 0.47
- Paper Targeting protein modification: a new direction for immunotherapy of pancreatic cancer. DOI 10.7150/ijbs.101861 ↗
- Paper Advancement of single-cell sequencing for clinical diagnosis and treatment of pancreatic cancer. DOI 10.3389/fmed.2023.1213136 ↗
Jie J. Yao · 2 shared papers, 2023–2025 · strength 0.47
- Paper Targeting protein modification: a new direction for immunotherapy of pancreatic cancer. DOI 10.7150/ijbs.101861 ↗
- Paper Advancement of single-cell sequencing for clinical diagnosis and treatment of pancreatic cancer. DOI 10.3389/fmed.2023.1213136 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.